alexa

GET THE APP

Drug Screening And Discovery Using Human Pluripotent Stem Cell Derived Cells | 73558
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1536

Journal of Biotechnology & Biomaterials received 1536 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Drug screening and discovery using human pluripotent stem cell derived cells

17th EURO BIOTECHNOLOGY CONGRESS

Dong-Hun Woo

NEXEL Co. Ltd., South Korea

Keynote: J Biotechnol Biomater

DOI: 10.4172/2155-952X-C1-075

Abstract
Drug-induced toxicity is a main reason for withdrawals of new drugs in late clinical phases and post-launch of the drugs. Thus, development of predictive in vitro assay for early toxicity evaluation is important for drug discovery process. Here, we show various kind of cells derived from human pluripotent stem cells (hPSCs) that could be used for early toxicity evaluation of drug candidates. From our inducing differentiation technology, we have routinely produced highly pure population (≥98%) of hepatocytes and cardiomyocytes from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Furthermore, we optimized a culture condition of hPSC-derived functional cells suitable for toxicity tests in vitro, and we demonstrated the efficacy of our optimized hPSC-derived cell model for predicting toxicity against the several drugs. In conclusion, our hPSC-derived cell model could be a good alternative cell source for pre-clinical study such as predicting toxicity and efficacy test for the drugs, and translational research of disease cure.
Biography

Dong-Hun Woo is a Chief Technology Officer (CTO) at NEXEL Co., Ltd. He received his PhD in Stem Cell Biology from Korea University. During this time, he worked on tissue regeneration through directed differentiation of human pluripotent stem cells into target cell types of the liver, pancreas, and brain. After PhD course, he initially extended his research into cancer stem cells, studying the molecular mechanisms underlying tumorigenicity of cancer stem cells in glioblastoma at the Lerner Research Institute of Cleveland Clinic in Cleveland, OH, USA. Then, he has his expertise in stem cell biology human pluripotent cell fate specification by bringing genome editing strategies to bear on induced pluripotent stem (IPS) cell models of human genetic diseases at the University of Pennsylvania, PA, USA. His current project involves the generation of functional cells from human pluripotent stem cells for drug screening and toxicity tests as Head of research programs at NEXEL Co., Ltd.

Top